If you look at the chart for the iShares U.S. Medical Devices ETF (IHI) lately, you might think the sector is flatlining. After a decade of being the steady pulse of a healthcare portfolio, medical device stocks have entered 2026 in what can only be described as a state of cardiac arrest. Between the rising GLP-1 fever and a new wave of tariff-induced margin pressure, the sector is currently waiting for a jolt of electricity to bring it back to life. More News from Barchart What Are Medical Device Stoc ...

Core Viewpoint - Boston Scientific Corporation is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Investigation Details - The investigation is being conducted by the Law Offices of Frank R. Cruz on behalf of investors [1] - The focus of the investigation is on the company's actions and whether they have breached federal securities regulations [1]

Core Viewpoint - Pulse Biosciences, Inc. (PLSE) shares experienced a significant increase of 40.91 percent, rising by $5.60 to reach $19.29, likely due to the release of positive clinical data regarding the treatment of atrial fibrillation using its nPulse Cardiac Catheter [1]. Group 1 - The stock price opened at $14.95 and fluctuated between an intraday low of $14.72 and a high of $19.70 on the Nasdaq [2]. - Trading volume surged to approximately 0.65 million shares, significantly higher than the average daily volume of around 0.18 million shares [2]. - The first-in-human feasibility study successfully treated 150 patients with rapid procedure times and minimal adverse effects, with the data presented at the 31st Annual AF Symposium 2026 in Boston [2]. Group 2 - The stock is currently trading within its 52-week range of $12.56 to $22.75 [3].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation, alleging misleading representations and failure to disclose adverse business facts during the specified Class Period from July 25, 2024, to October 22, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities during the Class Period [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Integer - The complaint alleges that Integer overstated its competitive position and failed to properly disclose worsening sales of electrophysiology devices [3]. - It is claimed that Integer mischaracterized its growth drivers, contributing to misleading information provided to investors [3]. Group 3: Stock Price Impact - Following a sales guidance reduction announced on October 23, 2025, Integer's stock price fell by $35.22 per share, representing a decline of more than 32% in a single trading day [4].

As filed with the U.S. Securities and Exchange Commission on February 6, 2026 Registration No. 333-292260 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 3842 86-1369123 Approximate date of commencement of proposed sale to the p ...

As filed with the U.S. Securities and Exchange Commission on February 6, 2026 Registration No. 333-292260 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear Parkw ...

Company Overview - Haemonetics Corporation provides blood management solutions to blood and plasma collectors, hospitals, and healthcare providers globally, offering integrated devices, information management, and consulting services to enhance clinical outcomes in the blood supply chain [11]. Investment Potential - Haemonetics is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid investment potential [12]. - The company has a Growth Style Score of B, forecasting a year-over-year earnings growth of 8.1% for the current fiscal year, with a recent upward revision in earnings estimates [12]. - The Zacks Consensus Estimate for Haemonetics has increased by $0.01 to $4.94 per share, and the company has an average earnings surprise of +6.8% [12]. Recommendation - With a strong Zacks Rank and favorable Growth and VGM Style Scores, Haemonetics is recommended for investors looking for growth opportunities [13].

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [3] - The Growth Score assesses a company's financial health and future outlook through projected and historical earnings, sales, and cash flow [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for stock selection [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [8] - For optimal returns, stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended [9] - Stocks with lower ranks but high Style Scores may still face downward price pressure due to negative earnings forecasts [10] Company Spotlight: Align Technology - Align Technology, based in California, specializes in clear aligner therapy and digital services for dentistry [11] - The company holds a Zacks Rank of 2 (Buy) and a VGM Score of B, with a Value Style Score of B, supported by a forward P/E ratio of 15.93 [12] - Recent upward revisions in earnings estimates and a Zacks Consensus Estimate of $11.02 per share for fiscal 2026 highlight its potential [12] - With strong rankings and favorable Style Scores, Align Technology is positioned as a compelling investment opportunity [13]

Core Insights - The latest Hurun China 500 list reveals the rankings of 500 non-state-owned enterprises in China, with a notable increase in the entry threshold to 34 billion RMB, a rise of nearly 30% compared to the previous year [1] - The list features 95 new entrants primarily from sectors such as consumer electronics, AI computing power, and new energy, while 99 companies dropped off the list, indicating a trend of fluctuation among companies [1] Group 1: Company Performance - Tencent's value reached 5.3 trillion RMB, marking a 50% increase, driven by strong performances in gaming, advertising, and fintech [2][3] - The "Shenzhen Four Sisters"—Huawei, BYD, Tencent, and China Ping An—are all in the top 10, with values of 850 billion RMB, 872 billion RMB, and 1.05 trillion RMB respectively, reflecting the resilience of Shenzhen's economy [3] - DJI, headquartered in Shenzhen, saw its value double due to its strong position in the consumer drone market and growth in overseas markets [5] Group 2: Industry Trends - The real estate sector saw a decline, with the number of listed companies dropping from 19 to 12 [1] - The Yangtze River Delta region has 161 companies in the Hurun China 500, accounting for 32% of the total, while the Guangdong-Hong Kong-Macau Greater Bay Area has 108 companies, representing 22% [4] - The report highlights that sectors such as AI computing, consumer electronics, innovative pharmaceuticals, and entertainment are key drivers of high-quality development in China's private economy [5]

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Picard was the subject of a fraudulent stock promotion scheme involving ...